MA Financial trades at $9.19 versus $11.41 fair value (24% upside). Strong execution with MA Money profitability inflection, 74% recurring revenue, 34% AUM growth. ROIC 19.0% vs WACC 9.2%. Quality score 7.8/10.
View noteRegis Healthcare acquiring aggressively at 7.5x EBITDA with $99m cash, 74 homes, $90m Q1 RAD inflows signal recovery, but valuation incomplete—integration execution critical.
View noteNorthern Star Resources: Australia's #2 gold producer trading at 102% premium to A$12.60 fair value. Operational excellence meets valuation excess with 51% downside risk.
View noteAttractive rating with fair value $4.61 vs current $4.505. Strong operational momentum with 3.1% FUMA growth to $340.5bn and positive $1.0bn net inflows. Trading at 42% discount to peers (7.4x vs 12.8x EV/EBITDA) despite comparable quality.
View noteTrading at 48% discount to peers despite 31.1% margins and 96% franchise retention. Fair value $3.62 vs current $1.83 implies 98% upside potential.
View noteSouth32 trades at 18% premium to $2.62 fair value with challenging risk-reward dynamics. ROIC 8.7% trails WACC 10.95%. High terminal dependency creates valuation uncertainty.
View notePremium wealth platform leader trading at 35% discount to $0.91 fair value, with 15.2% ROIC and 95% recurring revenue model targeting HNW growth.
View noteSpecialist SME bank with 16% loan growth and NPS +53, trading at $1.73 vs $1.01 fair value. Strong execution but overvalued at current levels.
View noteUndervalued base metals producer with 232% upside potential. Fair value $0.63 vs current $0.19. Strong EBITDA margins 35.5%, net cash position, targeting 40kt copper equivalent by FY28.
View noteFair value $0.121 vs current $0.225 (47% overvalued). 95% revenue CAGR forecast, 79% customer concentration, 68% failure probability. Speculative growth only.
View noteFair value $0.051 vs current $0.24 implies 79% downside. Strong defence positioning overwhelmed by extreme valuation and persistent cash burn through 2030.
View noteFair value $20.62 vs current $20.90. Corporate Trust moat with 45%+ margins. J O Hambro turnaround critical. Expected 3-year returns 2.5% annually.
View note